SCHEMBL6370637

SCHEMBL6370637

COc1cccc(-c2nn(C(=O)OC(C)(C)C)c3cc([N+](=O)[O-])ccc23)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 4/20 0.47
MAP2K4 P45985 1/20 0.45
F2 P00734 3/20 0.44
PLAU P00749 3/20 0.44
CTRB1 P17538 3/20 0.44
RIPK2 O43353 1/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
CASP3 P42574 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAOB P27338 1/20 0.41
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ABCG2 Q9UNQ0 4/20 0.38
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
CSNK2A1 P68400 1/20 0.38
ADORA2A P29274 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6591594 0.95 MAP2K4 (0.43) ELANEMAP2K4F2PLAUCTRB1
SCHEMBL6375106 0.88 L3MBTL1 (0.52) ELANEMAP2K4F2PLAUCTRB1
SCHEMBL6371415 0.87 ELANE (0.53) ELANEMAP2K4F2PLAUCTRB1
SCHEMBL6370591 0.84 RIPK2 (0.50) MAP2K4RIPK2LMNAADORA2AMAPT
SCHEMBL6369994 0.83 F12 (0.42) ELANEMAP2K4F2PLAUCTRB1
SCHEMBL6370930 0.82 ELANE (0.48) ELANEMAP2K4F2PLAUCTRB1
SCHEMBL6370634 0.81 F2 (0.41) ELANEMAP2K4F2PLAUCTRB1
SCHEMBL6369581 0.80 ELANE (0.39) ELANEMAP2K4F2PLAUCTRB1
SCHEMBL6370749 0.80 L3MBTL1 (0.39) ELANEMAP2K4F2PLAUCTRB1
SCHEMBL6370191 0.80 PTGS2 (0.40) ELANEMAP2K4F2PLAUCTRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113370-A1 Therapeutic substituted indazole derivatives ASTRAZENECA AB (SE) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113370-A1 Therapeutic substituted indazole derivatives NR4A3, CBR3, NR3C2 ELANE 4606/4885MAP2K4 2785/4885F2 3965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.